Skip to content
Review Open access

Interpreting the triglyceride–glucose index and its derived indices in metabolic dysfunction-associated steatotic liver disease: clinical utility and evidence gaps

Aug 2026 · Frontiers in Medicine · Vol 13 · 0 citations · 41 references
Medicine

TL;DR

This review examines the clinical interpretation, biological context, and current limitations of the TyG index and its anthropometric and inflammatory derivatives in MASLD and recommends it be considered a metabolic risk marker rather than a stand-alone diagnostic test for MASLD or MASH.

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is common, yet early disease often remains unrecognized. The triglyceride–glucose (TyG) index, calculated from fasting triglyceride and glucose concentrations, has emerged as an accessible surrogate marker of metabolic dysfunction. This review examines the clinical interpretation, biological context, and current limitations of the TyG index and its anthropometric and inflammatory derivatives in MASLD. Current evidence links higher TyG-related measures to prevalent steatosis, fibrosis markers, and selected extrahepatic outcomes. Indices incorporating body mass index, waist circumference, or waist-to-height ratio may improve risk discrimination in some settings, particularly when body-fat distribution is informative. However, their performance varies according to population characteristics, disease definition, reference standard, and clinical purpose. TyG is not a direct measure of hepatic or peripheral insulin resistance, liver inflammation, or fibrosis. It should therefore be considered a metabolic risk marker rather than a stand-alone diagnostic test for MASLD or MASH. Important limitations include the predominance of cross-sectional evidence, heterogeneity among NAFLD, MAFLD, and MASLD definitions, variable cutoff values, and component overlap between TyG-derived indices and cardiometabolic diagnostic criteria. Evidence for liver-specific hard outcomes remains limited. Future studies should directly compare TyG-related markers with established metabolic and liver-directed tests in diverse prospective cohorts, using standardized repeated measurements and outcomes including progressive fibrosis, cirrhosis, hepatocellular carcinoma, and liver-related death. At present, TyG-related measures may complement, but cannot replace, liver-specific assessment.

Read PDF

Similar papers

Review Open access Oct 2026

Prognostic value of triglyceride-glucose index combined with inflammatory biomarkers for mortality in metabolic dysfunction-associated steatotic liver disease

ROC curve analysis revealed that TyG-MLR displayed superior predictive performance for all-cause and cardiovascular mortality at 1, 3, and 5-year follow-ups, whereas TyG-lgSII emerged as the most accurate predictor for diabetes-related mortality.

Fei Jiang, Tian-Yi Chen, Jia-Qi Zhang et al. · 0 citations
Open access Sep 2026

Association between atherogenic index of plasma and metabolic dysfunction-associated steatotic liver disease in Egyptian population: a case–control study

Alyrogenic index of plasma is independently and positively associated with MASLD, more degree of hepatic steatosis, insulin resistance and low adiponectin level, and using AIP alone or in combination with BMI could alarm clinicians to further investigate for presence of MASLD in individuals at outpatient clinics.

Manal Abdel-Mageed, Marium M. Shamaa, M. Labane et al. · 0 citations
Open access Oct 2026

Association of cumulative triglyceride-glucose index with incident metabolic dysfunction-associated steatotic liver disease: a cohort study

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing global public health burden with progressive hepatic and cardiometabolic consequences. Insulin resistance is central to MASLD pathogenesis, and the triglyceride-glucose (TyG) index is a practical surrogate marker for insulin resistance...

S. Kang, N. Zhang, W. Chen et al. · 0 citations
Review Open access Sep 2026

Comparative prognostic performance of triglyceride-glucose-adiposity indices for mortality in adults with metabolic dysfunction-associated steatotic liver disease

Composite indices integrating insulin resistance and adiposity may improve mortality risk stratification in metabolic dysfunction-associated steatotic liver disease (MASLD). We evaluated eight triglyceride-glucose (TyG)-related indices in 6,159 U.S. adults with MASLD from the 1999–2018 National Health and Nutrition E...

Kai Zhang, Na-Ni Long, Long-Hao Zhang et al. · 0 citations
Open access Oct 2026

Triglyceride-Glucose Index and Systemic Inflammatory Markers in Polyendocrine Metabolic Ovarian Syndrome (Polycystic Ovary Syndrome): A Cross-Sectional Study

Highlights What are the main findings? In women with polyendocrine metabolic ovarian syndrome (PMOS), the triglyceride-glucose (TyG) index was independently associated with hemogram-derived inflammatory indices after adjustment for body mass index (BMI) and age, whereas C-reactive protein (CRP) was associated only with...

Meryem Keçeci Oğuzhanoğlu, Kursat Oguzhanoglu · 0 citations
Open access Oct 2026

Lipid Accumulation Product Index and Triglyceride-Glucose Index as Predictors of Metabolic Syndrome in Young Adults: A Cross-Sectional Study

Both the LAP index and the TyG index are reliable, cost-effective surrogate tools for early identification of metabolic syndrome in young adults and merit integration into routine clinical practice for early metabolic risk stratification.

Manmohan Kumar Dumpa, Sibi Chakravarthy, G. Josephraj · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.